A high expression of CD31 and VEGF was affirmed by recent studies to correlate with poorer clinical outcomes, including reoccurrence and survival rates, especially concerning laryngeal cancer at the early stage [13–15]. The gene discussed is PECAM1; the disease is laryngeal carcinoma.